UNSPSC 51343820: Lamivudine/nevirapine/zidovudine

This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The third component, ZIDOVUDINE, has US FDA Unique Ingredient Identifier of 4B9XT59T7S.

UNSPSC 51343820 Lamivudine/nevirapine/zidovudine is a Commodity code that does not align with recent state and local procurement activity. The code identifies a specific antiretroviral drug combination used in HIV treatment, yet the recent opportunities tagged with this code span emergency medical services software (drug-dosage calculation applications), long-term care pharmaceutical services, EMS pharmaceuticals and supplies, pharmacy benefits networks, naloxone distribution, forensic drug standards, and opioid settlement grants—none of which involve lamivudine/nevirapine/zidovudine procurement or HIV antiretroviral therapy. The mismatch suggests either tagging error in the source data or a cataloging inconsistency in how these opportunities were indexed.

State and local governments posting under this code in the recent record include Collier County (Florida), Dane County (Wisconsin), the City of Tucson (Arizona), West Texas Centers for Mental Health and Mental Retardation, Seminole County (Florida), Pinellas County (Florida), the District of Columbia, Washington County (Oregon), and the City of Palm Bay (Florida)—a geographically dispersed set spanning emergency services, behavioral health, long-term care, and forensic laboratory contexts. Representative recent opportunities include Dane County's RFP for comprehensive pharmaceutical services to Badger Prairie Health Care Center due October 22, 2026, the City of Tucson Fire Department's RFP for BLS/ALS pharmaceuticals and VendNovation vending systems (due June 24, 2026), West Texas Centers' RFP for prescription and pharmacy services across 35 sites in 23 counties (due August 21, 2026), and Seminole County's IFB for 1,900 units of naloxone and 800 drug deactivation systems annually. The code shows active purchasing but not in the antiretroviral space; business development professionals should verify whether their offerings match the actual procurement need before pursuing opportunities tagged under this code.